{"entity":{"id":"paper-checkmate-8hw-lancet-2025","kind":"paper","name":"CheckMate 8HW: nivolumab plus ipilimumab versus nivolumab alone in MSI-high metastatic colorectal cancer","aka":[],"tldr":"Dual immunotherapy with nivolumab and ipilimumab delayed progression more than nivolumab alone across all lines of treatment in microsatellite-unstable colorectal cancer, with about seven in ten patients progression-free at three years.","summary":"Phase 3 trial of 707 patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer randomised to nivolumab plus ipilimumab, nivolumab alone or chemotherapy; this report compares the two immunotherapy arms across all lines.\n\nProgression-free survival favoured the combination (hazard ratio 0.62; three-year rate about 68 versus 51 percent) with a higher response rate (71 versus 58 percent); grade 3 to 4 treatment-related adverse events were 22 versus 14 percent.","asOf":"2026-09-17","links":[{"label":"Lancet 2025","url":"https://doi.org/10.1016/S0140-6736(24)02848-4"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/39874977/"}],"tags":[],"related":[],"cancers":["msi-high-colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["ipilimumab","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-8hw"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2025,"doi":"10.1016/S0140-6736(24)02848-4","pmid":"39874977","authors":"André T, Elez E, Lenz HJ, et al.","paperType":"rct","findings":["Progression-free survival hazard ratio 0.62 for the combination vs nivolumab alone.","Objective response 71 percent vs 58 percent."],"whatItMeans":"Nivolumab-ipilimumab is a first-line standard for microsatellite-unstable metastatic colorectal cancer alongside pembrolizumab, with the trade-off of more immune toxicity for deeper and more durable control.","caveats":["Overall survival data immature at this report.","The earlier comparison with chemotherapy was first line only."],"changedPractice":true,"participants":707},"route":"/key-papers/paper-checkmate-8hw-lancet-2025/","neighbours":{"cancer":[{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"checkmate-8hw","kind":"trial","name":"CheckMate 8HW","route":"/trials/checkmate-8hw/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}